Brad A. Racette, MD, FAAN

Kemper and Ethel Marley Professor and Chair of Neurology

• (602) 406-6262
• Fax: (602) 406-6261

Find a Clinical Trial

Accepting New Patients

Brad A. Racette, MD, FAAN, is a neurologist in the Muhammad Ali Parkinson Center, the Kemper and Ethel Marley Professor, and Chair of Neurology at Barrow Neurological Institute. He is board certified in neurology by the American Board of Psychiatry and Neurology.

Dr. Racette’s clinical expertise includes the diagnosis and management of all types of movement disorders, and he has more than 30 years of experience in the use of botulinum toxin for limb disorders. He is a fellow of the American Academy of Neurology and the American Neurological Association. He is the past chairman of the Neurological, Aging, and Musculoskeletal Epidemiology Study Section at the National Institutes of Health (NIH) and a current member of the National Advisory Environmental Health Sciences Council for the National Institute of Environmental Health Sciences. He has served as an advisor for numerous international regulatory agencies. He is an honorary professor of public health at the University of Witwatersrand in Johannesburg, South Africa, and a professor emeritus at Washington University.

Dr. Racette earned his medical degree from the Feinberg School of Medicine at Northwestern University in Chicago and his bachelor’s degree in molecular biology from Princeton University in New Jersey. He completed his neurology residency and a fellowship in movement disorders at Washington University School of Medicine in St. Louis. He then joined the faculty at Washington University, where he held the roles of Robert Allan Finke professor of neurology and executive vice-chairman of neurology.

Dr. Racette’s research focuses on manganese neurotoxicity, environmental risk factors for Parkinson’s disease, and administrative data studies of Parkinson’s disease and other neurologic diseases. He has authored over 175 peer-reviewed publications. He is supported by the NIH, Michael J. Fox Foundation, Department of Defense, Cure Alzheimer’s Fund, Northeast ALS Consortium, and American Parkinson Disease Association.